Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13556668 | 0.84 | SNCA (0.48) | SNCA | |
| Bromide SCHEMBL2586939 | 0.82 | SNCA (0.47) | SNCA | |
| Bromide SCHEMBL27892000 | 0.82 | SNCA (0.47) | SNCA | |
| SCHEMBL2594198 | 0.74 | NMT1 (0.33) | SNCA | |
| SCHEMBL18913249 | 0.74 | ALDH1A1 (0.35) | — | |
| SCHEMBL3310694 | 0.71 | TSHR (0.34) | SNCA | |
| SCHEMBL12592448 | 0.71 | TSHR (0.34) | SNCA | |
| SCHEMBL12592437 | 0.67 | S100B (0.41) | — | |
| SCHEMBL2587087 | 0.65 | BCHE (0.42) | SNCA | |
| SCHEMBL29636443 | 0.65 | BCHE (0.42) | SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585073-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8828986-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828986-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8809317-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809317-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8785434-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2585073-A1 | ANTIVIRAL COMPOUNDS | Prostetta Antiviral Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120302556-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302556-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120270854-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270854-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011137447-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | SNCA 1569/4885 |
| US-20120270854-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | SNCA 734/4885 |
| US-20120302556-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | SNCA 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.